Alexza Pharma (ALXA) Income Statement

Click line-items for a historical chart and %

Revenue	673K
Research and development
General and administrative	1.81M
Restructuring charges
Acquired in-process research and development
Total operating expenses	10.66M
Loss from operations	-9.98M
Loss on change in fair value of contingent consideration liability
Interest and other income/ (expense), net	115K
Interest expense	-2.05M
Net loss
Consideration paid in excess of noncontrolling interest
Net loss attributed to noncontrolling interest in Symphony Allegro, Inc.
Net loss attributable to Alexza common stockholders	-3.02M
Net loss per share attributable to Alexza common stockholders	-0.16
Shares used to compute basic and diluted net loss per share attributable to Alexza common stockholders

Entities mentioned with ALXA

View All Entities